Compare ZKH & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZKH | LXRX |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.5M | 541.5M |
| IPO Year | 2023 | 2000 |
| Metric | ZKH | LXRX |
|---|---|---|
| Price | $3.20 | $1.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 211.9K | ★ 2.0M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,236,195,501.00 | $70,864,000.00 |
| Revenue This Year | $2.44 | $56.61 |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $2.50 | $0.28 |
| 52 Week High | $4.03 | $1.66 |
| Indicator | ZKH | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 49.99 |
| Support Level | $2.93 | $1.34 |
| Resistance Level | $3.49 | $1.47 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 48.67 | 50.00 |
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.